These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8061250)

  • 1. Plasmatic parameters of fibrin formation and degradation in cancer patients: correlation between fibrinopeptide A and D-dimer.
    Sagripanti A; Carpi A; Baicchi U; Grassi B
    Biomed Pharmacother; 1993; 47(6-7):235-9. PubMed ID: 8061250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
    Gadducci A; Baicchi U; Marrai R; Del Bravo B; Fosella PV; Facchini V
    Gynecol Oncol; 1994 Jun; 53(3):352-6. PubMed ID: 8206409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo measurements of fibrin formation and degradation in nephrotic patients.
    Sagripanti A; Cupisti A; Baicchi U; Ferdeghini M; Barsotti G
    Int J Clin Lab Res; 1994; 24(2):113-6. PubMed ID: 7919427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of some hemostatic parameters in patients with cervical carcinoma.
    Gadducci A; Baicchi U; Del Bravo B; Facchini V; Marrai R; Sagripanti A; Fioretti P
    Eur J Gynaecol Oncol; 1990; 11(3):215-8. PubMed ID: 2209641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease.
    Sun S; Karsdal MA; Mortensen JH; Luo Y; Kjeldsen J; Krag A; Jensen MD; Bay-Jensen AC; Manon-Jensen T
    J Gastrointestin Liver Dis; 2019 Jun; 28():175-182. PubMed ID: 31204415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status.
    Gadducci A; Baicchi U; Marrai R; Facchini V; del Bravo B; Fosella PV; Fioretti P
    Gynecol Oncol; 1993 Jun; 49(3):354-8. PubMed ID: 8314538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
    Mombelli G; Monotti R; Haeberli A; Straub PW
    Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases].
    Murakoshi T
    Hokkaido Igaku Zasshi; 1982 May; 57(3):351-63. PubMed ID: 6957368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of fibrinopeptide A (FpA) as a marker for gastrointestinal cancers before and after surgery.
    Abbasciano V; Levato F; Zavagli G
    Med Oncol Tumor Pharmacother; 1987; 4(2):75-9. PubMed ID: 3669780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface-dependent fibrinopeptide A accessibility to thrombin.
    Geer CB; Rus IA; Lord ST; Schoenfisch MH
    Acta Biomater; 2007 Sep; 3(5):663-8. PubMed ID: 17540627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin formation and degradation in patients with arteriosclerotic disease.
    Herren T; Stricker H; Haeberli A; Do DD; Straub PW
    Circulation; 1994 Dec; 90(6):2679-86. PubMed ID: 7994808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for sequential cleavage of fibrinopeptides upon fibrin assembly.
    Pechik I; Yakovlev S; Mosesson MW; Gilliland GL; Medved L
    Biochemistry; 2006 Mar; 45(11):3588-97. PubMed ID: 16533041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
    Weitz JI; Leslie B; Hudoba M
    Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
    Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
    J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinogen metabolism and plasma fibrinopeptide A in disseminated neoplasms].
    Mombelli G; Roux A; Hofmann V; Straub PW
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1901. PubMed ID: 531571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clotting activation and impairment of fibrinolysis in malignancy.
    Rocha E; Páramo JA; Fernández FJ; Cuesta B; Hernández M; Paloma MJ; Rifón J
    Thromb Res; 1989 Jun; 54(6):699-707. PubMed ID: 2506659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction.
    Lindahl AK; Sandset PM; Abildgaard U
    Haemostasis; 1990; 20(5):253-62. PubMed ID: 2289706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood coagulation after long distance running: antithrombin III prevents fibrin formation.
    Bärtsch P; Haeberli A; Straub PW
    Thromb Haemost; 1990 Jun; 63(3):430-4. PubMed ID: 2402746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
    Widström O; Kockum C; Nilsson BS
    Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.